Risk of Akathisia Associated With Atypical Antipsychotics

被引：0

作者：

Agarkar, S.

Anthony, D.

Ferrando, S.

机构：

来源：

JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES | 2013年 / 25卷 / 01期

关键词：

D O I：

10.1176/appi.neuropsych.12030061

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：E46 / E47

页数：2

共 7 条

[1]

[Anonymous], 1985, AM J PSYCHIAT, V142, P46

[2]

Drake RE, 1994, BRIT J PSYCHIAT, V164, P365

[3] Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms [J].

Franberg, Olivia ;

Marcus, Monica M. ;

Ivanov, Vladimir ;

Schilstrom, Bjorn ;

Shahid, Mohammed ;

Svensson, Torgny H. .

PSYCHOPHARMACOLOGY, 2009, 204 (02) :251-264

[4] Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials [J].

Kane, John M. ;

Barnes, Thomas R. E. ;

Correll, Christoph U. ;

Sachs, Gary ;

Buckley, Peter ;

Eudicone, James ;

McQuade, Robert ;

Tran, Quynh-Van ;

Pikalov, Andrei, III ;

Assuncao-Talbott, Sheila .

JOURNAL OF PSYCHOPHARMACOLOGY, 2010, 24 (07) :1019-1029

[5]

Kinghorn Warren A, 2005, Expert Rev Neurother, V5, P297, DOI 10.1586/14737175.5.3.297

[6] Evaluation of the clinical efficacy of asenapine in schizophrenia [J].

Minassian, Arpi ;

Young, Jared W. .

EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (12) :2107-2115

[7]

Thomas RE, 2003, J PSYCHOPHARMACOL, P365

← 1 →